243 related articles for article (PubMed ID: 16288403)
1. Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America.
Girardi E; Sabin CA; d'Arminio Monforte A; Hogg B; Phillips AN; Gill MJ; Dabis F; Reiss P; Kirk O; Bernasconi E; Grabar S; Justice A; Staszewski S; Fätkenheuer G; Sterne JA;
Clin Infect Dis; 2005 Dec; 41(12):1772-82. PubMed ID: 16288403
[TBL] [Abstract][Full Text] [Related]
2. Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting?
Pettit AC; Jenkins CA; Stinnette SE; Rebeiro PF; Blackwell RB; Raffanti SP; Shepherd BE; Sterling TR
J Acquir Immune Defic Syndr; 2011 Aug; 57(4):305-10. PubMed ID: 21423024
[TBL] [Abstract][Full Text] [Related]
3. Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001.
Miranda A; Morgan M; Jamal L; Laserson K; Barreira D; Silva G; Santos J; Wells C; Paine P; Garrett D
PLoS One; 2007 Sep; 2(9):e826. PubMed ID: 17786198
[TBL] [Abstract][Full Text] [Related]
4. Incidence of tuberculosis after HAART initiation in a cohort of HIV-positive patients in Burkina Faso.
Dembélé M; Saleri N; Carvalho AC; Saouadogo T; Hien AD; Zabsonre I; Koala ST; Simporé J; Matteelli A
Int J Tuberc Lung Dis; 2010 Mar; 14(3):318-23. PubMed ID: 20132623
[TBL] [Abstract][Full Text] [Related]
5. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients.
Antiretroviral Therapy Cohort Collaboration
J Acquir Immune Defic Syndr; 2007 Dec; 46(5):607-15. PubMed ID: 18043315
[TBL] [Abstract][Full Text] [Related]
6. Timing of Antiretroviral Treatment, Immunovirologic Status, and TB Risk: Implications for Testing and Treatment.
Pettit AC; Mendes A; Jenkins C; Napravnik S; Freeman A; Shepherd BE; Dowdy D; Gill J; Rachlis A; Moore R; Sterling TR;
J Acquir Immune Defic Syndr; 2016 Aug; 72(5):572-8. PubMed ID: 27049511
[TBL] [Abstract][Full Text] [Related]
7. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies.
Chêne G; Sterne JA; May M; Costagliola D; Ledergerber B; Phillips AN; Dabis F; Lundgren J; D'Arminio Monforte A; de Wolf F; Hogg R; Reiss P; Justice A; Leport C; Staszewski S; Gill J; Fatkenheuer G; Egger ME;
Lancet; 2003 Aug; 362(9385):679-86. PubMed ID: 12957089
[TBL] [Abstract][Full Text] [Related]
8. High rates of tuberculosis in patients accessing HAART in rural South Africa.
Naidoo K; Karim QA; Bhushan A; Naidoo K; Yende-Zuma N; McHunu PK; Frohlich J; Karim F; Upfold M; Kocheleff P; Abdool Karim SS
J Acquir Immune Defic Syndr; 2014 Apr; 65(4):438-46. PubMed ID: 24256629
[TBL] [Abstract][Full Text] [Related]
9. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort.
Lawn SD; Badri M; Wood R
AIDS; 2005 Dec; 19(18):2109-16. PubMed ID: 16284460
[TBL] [Abstract][Full Text] [Related]
10. Association of highly active antiretroviral treatment with incident tuberculosis in people living with HIV/AIDS.
Yen YF; Jen IA; Chuang PH; Chen M; Lan YC; Lee CY; Arthur Chen YM
Ann Epidemiol; 2018 Dec; 28(12):886-892.e3. PubMed ID: 29656849
[TBL] [Abstract][Full Text] [Related]
11. High incidence of tuberculosis in the first year of antiretroviral therapy in the Botswana National antiretroviral therapy programme between 2011 and 2015.
Mupfumi L; Moyo S; Shin SS; Wang Q; Zetola N; Molebatsi K; Nnawa J; Kgwaadira BT; Bewlay L; Chebani T; Iketleng T; Mogashoa T; Makhema J; Musonda RM; Essex M; Kasvosve I; Gaseitsiwe S
AIDS; 2019 Dec; 33(15):2415-2422. PubMed ID: 31764106
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of isoniazid preventative therapy in reducing incidence of active tuberculosis among people living with HIV/AIDS in public health facilities of Addis Ababa, Ethiopia: a historical cohort study.
Semu M; Fenta TG; Medhin G; Assefa D
BMC Infect Dis; 2017 Jan; 17(1):5. PubMed ID: 28049455
[TBL] [Abstract][Full Text] [Related]
13. Incidence of tuberculosis in HIV-infected patients receiving HAART: interaction between TST and CD4 count.
Martín-Echevarria E; Rodríguez-Zapata M; Torralba M; Fernández JM; Moreno A; Casado JL; Dronda F; Pérez-Elías MJ; Navas E; Moreno S
Int J Tuberc Lung Dis; 2011 Oct; 15(10):1347-52. PubMed ID: 22283893
[TBL] [Abstract][Full Text] [Related]
14. Post-HAART tuberculosis in adults and adolescents with HIV in India: incidence, clinical and immunological profile.
Rajasekaran S; Raja K; Jeyaseelan L; Vijilat S; Priya K; Mohan K; Parvez A; Mahilmaran A; Chandrasekar C
Indian J Tuberc; 2009 Apr; 56(2):69-76. PubMed ID: 19810588
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
[TBL] [Abstract][Full Text] [Related]
16. Incidence of tuberculosis and early mortality in a large cohort of HIV infected patients receiving antiretroviral therapy in a tertiary hospital in Addis Ababa, Ethiopia.
Kassa A; Teka A; Shewaamare A; Jerene D
Trans R Soc Trop Med Hyg; 2012 Jun; 106(6):363-70. PubMed ID: 22521216
[TBL] [Abstract][Full Text] [Related]
17. Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden.
Bonnet MM; Pinoges LL; Varaine FF; Oberhauser BB; O'Brien DD; Kebede YY; Hewison CC; Zachariah RR; Ferradini LL
AIDS; 2006 Jun; 20(9):1275-9. PubMed ID: 16816556
[TBL] [Abstract][Full Text] [Related]
18. Factors impacting early mortality in tuberculosis/HIV patients: differences between subjects naïve to and previously started on HAART.
Schmaltz CA; Santoro-Lopes G; Lourenço MC; Morgado MG; Velasque Lde S; Rolla VC
PLoS One; 2012; 7(9):e45704. PubMed ID: 23049842
[TBL] [Abstract][Full Text] [Related]
19. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies.
May M; Sterne JA; Sabin C; Costagliola D; Justice AC; Thiébaut R; Gill J; Phillips A; Reiss P; Hogg R; Ledergerber B; D'Arminio Monforte A; Schmeisser N; Staszewski S; Egger M;
AIDS; 2007 May; 21(9):1185-97. PubMed ID: 17502729
[TBL] [Abstract][Full Text] [Related]
20. Effect of highly active antiretroviral treatment on TB incidence among HIV infected children and their clinical profile, retrospective cohort study, South West Ethiopia.
Tiruneh F; Deyas Y
Sci Rep; 2020 Dec; 10(1):21468. PubMed ID: 33293656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
